Allium sativum: A potential natural compound for NAFLD prevention and treatment

Introduction Non-alcoholic fatty liver disease (NAFLD) results from an excessive accumulation of fat particles that causes liver inflammation, which ultimately causes liver damage. There is still considerable uncertainty about the effects of any nutritional supplements compared to no additional intervention. This review aimed to evaluate the efficacy of Allium sativum (A. sativum), known as garlic, in preventing and treating NAFLD. Methods A systematic search based on a search strategy consisting of two components of “NAFLD” and “Allium sativum” in databases including PubMed, Web of Science (WoS), and SCOPUS was conducted on papers evaluating the effects of A. sativum on NAFLD treatment and prevention. We obtained studies from inception until 20 September 2022, followed by study selection and data extraction based on our eligibility criteria. Consequently, qualitative and quantitative synthesis was conducted. Results Our qualitative analysis reveals that A. sativum consumption is linked to the prevention of NAFLD, especially in males, although qualitative data in this study regarding the therapeutic properties of NAFLD was controversial. Our meta-analysis showed that NAFLD patients treated with A. sativum have significantly declined aminotransferase levels. That is to say, our meta-analysis revealed a lower alanine transaminase (ALT) (SMD = −0.580, 95%CI = −0.822 to −0.338), and aspartate transaminase (AST(SMD = −0.526, 95%CI = −0.767 to −0.284) in NAFLD patients treated with A. sativum compared to the placebo group. Also, pooling data from case-control studies showed that A. sativum consumption decreases the odds of being diagnosed with NAFLD by 46% (OR = 0.538, 95%CI = 0.451–0.625). Conclusion A. sativum consumption is not merely associated with NAFLD prevention but also results in a considerable decline in blood aminotransferase levels in patients diagnosed with NAFLD. To put it simply, A. sativum is linked to a decline in AST and ALT, which are considered reliable biomarkers of NAFLD response to treatment. Nevertheless, A. sativum is insufficient to improve NAFLD independent of other dietary amendments and lifestyle modifications.

[1]  G. Tarantino,et al.  It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them? , 2021, International Journal of Molecular Sciences.

[2]  G. Tarantino,et al.  Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. , 2021, Metabolism: clinical and experimental.

[3]  A. Alirezaei,et al.  Efficacy of Oral Administration of Allium sativum Powder “Garlic Extract” on Lipid Profile, Inflammation, and Cardiovascular Indices among Hemodialysis Patients , 2021, Evidence-based complementary and alternative medicine : eCAM.

[4]  Abbas Ali Sangouni,et al.  Effects of garlic powder supplementation on metabolic syndrome components, insulin resistance, fatty liver index, and appetite in subjects with metabolic syndrome: A randomized clinical trial , 2021, Phytotherapy research : PTR.

[5]  R. Loomba,et al.  Treatment candidacy for pharmacologic therapies for NASH. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  J. Freudenheim,et al.  Types of garlic and their anticancer and antioxidant activity: a review of the epidemiologic and experimental evidence , 2021, European Journal of Nutrition.

[7]  N. Sandhu,et al.  Herbal Medicines for the Treatment of Nonalcoholic Steatohepatitis , 2021, Current Hepatology Reports.

[8]  S. Wei,et al.  Efficacy of resveratrol supplementation on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. , 2020, Complementary therapies in medicine.

[9]  M. Chourdakis,et al.  The impact of Silymarin in patients with Non-Alcoholic Fatty Liver Disease: a systematic review and meta-analysis: Silymarin in NAFLD: A systematic review , 2020 .

[10]  M. Rouhani,et al.  Therapeutic Effects of Garlic on Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Patients: A Randomized Clinical Trial , 2020, Diabetes, metabolic syndrome and obesity : targets and therapy.

[11]  Nabiyah Bakhtawar,et al.  Vitamin E as an Adjuvant Treatment for Non-alcoholic Fatty Liver Disease in Adults: A Systematic Review of Randomized Controlled Trials , 2020, Cureus.

[12]  Ning Wang,et al.  Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application , 2020, Frontiers in Pharmacology.

[13]  Abbas Ali Sangouni,et al.  Effect of garlic powder supplementation on hepatic steatosis, liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease: a double-blind randomised controlled clinical trial , 2020, British Journal of Nutrition.

[14]  M. Mazidi,et al.  Effects of green tea or green tea catechin on liver enzymes in healthy individuals and people with nonalcoholic fatty liver disease: A systematic review and meta‐analysis of randomized clinical trials , 2020, Phytotherapy research : PTR.

[15]  A. McLachlan,et al.  Garlic (Allium sativum L.) in the management of hypertension and dyslipidemia – A systematic review , 2020 .

[16]  H. Poustchi,et al.  Association of allium vegetables intake and non-alcoholic fatty liver disease risk , 2020 .

[17]  F. Gonzalez,et al.  Herbal drug discovery for the treatment of nonalcoholic fatty liver disease , 2019, Acta pharmaceutica Sinica. B.

[18]  Y. Yılmaz,et al.  Characterization of Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease and Normal Aminotransferase Levels. , 2019, Journal of gastrointestinal and liver diseases : JGLD.

[19]  L. Adams,et al.  Lifestyle modification in NAFLD/NASH: Facts and figures , 2019, JHEP reports.

[20]  Shunming Zhang,et al.  Association between dietary raw garlic intake and newly diagnosed nonalcoholic fatty liver disease: A population-based study. , 2019, European journal of endocrinology.

[21]  K. Cusi,et al.  From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options , 2019, JHEP reports.

[22]  F. Tacke,et al.  Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis , 2019, Hepatology.

[23]  A. Amor,et al.  Dyslipidemia in nonalcoholic fatty liver disease , 2019, Current opinion in endocrinology, diabetes, and obesity.

[24]  Anahita Mansoori,et al.  Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta‐analysis of randomized controlled trials , 2019, Phytotherapy research : PTR.

[25]  Modified Newcastle-Ottawa Quality Assessment Scale (Cohort studies) , 2019 .

[26]  Andrew A. Li,et al.  The Role of Vitamin E in the Treatment of NAFLD , 2018, Diseases.

[27]  Andrew A. Li,et al.  Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD , 2018, Diseases.

[28]  J. Qin,et al.  Anti-hyperlipidemia of garlic by reducing the level of total cholesterol and low-density lipoprotein , 2018, Medicine.

[29]  E. Tsai,et al.  Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. , 2018, Clinics in liver disease.

[30]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[31]  A. Singal,et al.  Cardiovascular mortality among liver transplant recipients with nonalcoholic steatohepatitis in the United States—a retrospective study , 2017, Transplant international : official journal of the European Society for Organ Transplantation.

[32]  G. Sood,et al.  Non-alcoholic fatty liver disease and cardiovascular risk , 2017, World journal of gastrointestinal pathophysiology.

[33]  A. Elgebaly,et al.  Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis. , 2017, Journal of gastrointestinal and liver diseases : JGLD.

[34]  Feng Zhang,et al.  Diallyl Trisulfide Suppresses Oxidative Stress-Induced Activation of Hepatic Stellate Cells through Production of Hydrogen Sulfide , 2017, Oxidative medicine and cellular longevity.

[35]  B. Neuschwander‐Tetri,et al.  Practice patterns in NAFLD and NASH: real life differs from published guidelines , 2016, Therapeutic advances in gastroenterology.

[36]  Sung-Goo Kang,et al.  Efficacy and safety of fermented garlic extract on hepatic function in adults with elevated serum gamma-glutamyl transpeptidase levels: a double-blind, randomized, placebo-controlled trial , 2016, European Journal of Nutrition.

[37]  Nayoung Kim,et al.  Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study , 2015, Clinical and molecular hepatology.

[38]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[39]  Mary E Rinella,et al.  Nonalcoholic fatty liver disease: a systematic review. , 2015, JAMA.

[40]  A. Hosseini,et al.  A review on the effects of Allium sativum (Garlic) in metabolic syndrome , 2015, Journal of Endocrinological Investigation.

[41]  Yu Qin,et al.  Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[42]  K. Lee,et al.  Korean translation of the CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials , 2014, Epidemiology and health.

[43]  Shridevi Adaki,et al.  Garlic: Review of literature. , 2014, Indian journal of cancer.

[44]  Liang Shen,et al.  Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis. , 2014, Nutrition.

[45]  Chi-Tang Ho,et al.  Garlic essential oil protects against obesity-triggered nonalcoholic fatty liver disease through modulation of lipid metabolism and oxidative stress. , 2014, Journal of agricultural and food chemistry.

[46]  S. Nammi,et al.  Herbal Medicines for the Treatment of Nonalcoholic Steatohepatitis: Current Scenario and Future Prospects , 2014, Evidence-based complementary and alternative medicine : eCAM.

[47]  K. Kowdley,et al.  Controversies in the Diagnosis and Management of NAFLD and NASH. , 2014, Gastroenterology & hepatology.

[48]  M. Taniai,et al.  Characteristics and diagnosis of NAFLD/NASH , 2013, Journal of gastroenterology and hepatology.

[49]  S. Verma,et al.  Predictive value of ALT levels for non‐alcoholic steatohepatitis (NASH) and advanced fibrosis in non‐alcoholic fatty liver disease (NAFLD) , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[50]  Hyung Gyun Kim,et al.  S-allyl cysteine attenuates free fatty acid-induced lipogenesis in human HepG2 cells through activation of the AMP-activated protein kinase-dependent pathway. , 2013, The Journal of nutritional biochemistry.

[51]  Mahmudur Rahman,et al.  Antioxidant properties of raw garlic (allium sativum) extract , 2012 .

[52]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[53]  A. Nanji,et al.  Garlic-derived S-allylmercaptocysteine is a hepato-protective agent in non-alcoholic fatty liver disease in vivo animal model , 2012, European Journal of Nutrition.

[54]  A. Sanyal.  NASH: A global health problem , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

[55]  D. Moher,et al.  Nonalcoholic Fatty Liver Disease and Acute Ischemic Stroke , 2010 .

[56]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials , 2010, Obstetrics and gynecology.

[57]  B. Neuschwander‐Tetri,et al.  Lifestyle modification as the primary treatment of NASH. , 2009, Clinics in liver disease.

[58]  Min‐Jung Kang,et al.  Effect of Garlic and Aged Black Garlic on Hyperglycemia and Dyslipidemia in Animal Model of Type 2 Diabetes Mellitus , 2009 .

[59]  F. Schmidt.  Meta-Analysis , 2008 .

[60]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[61]  A. R.,et al.  Review of literature , 1960, American Potato Journal.

[62]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[63]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[64]  M. Thomson,et al.  Garlic [Allium sativum]: a review of its potential use as an anti-cancer agent. , 2003, Current cancer drug targets.

[65]  S. Caldwell,et al.  A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis , 2001, American Journal of Gastroenterology.

[66]  S. Ankri,et al.  Antimicrobial properties of allicin from garlic. , 1999, Microbes and infection.

[67]  N. Black.  CONSORT , 1996, The Lancet.

[68]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[69]  I. Parker.  Facts and figures. , 1973, The Probe.

[70]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.

[71]  Sharma,et al.  Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis , 2022 .